PH22020050135Y1 - Anti-diabetes compositions comprising standardized mangifera indica extract - Google Patents
Anti-diabetes compositions comprising standardized mangifera indica extractInfo
- Publication number
- PH22020050135Y1 PH22020050135Y1 PH22020050135U PH22020050135U PH22020050135Y1 PH 22020050135 Y1 PH22020050135 Y1 PH 22020050135Y1 PH 22020050135 U PH22020050135 U PH 22020050135U PH 22020050135 U PH22020050135 U PH 22020050135U PH 22020050135 Y1 PH22020050135 Y1 PH 22020050135Y1
- Authority
- PH
- Philippines
- Prior art keywords
- mangifera indica
- extract
- standardized
- ingredient
- indica extract
- Prior art date
Links
- 239000009247 Mangifera indica extract Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000004615 ingredient Substances 0.000 abstract 3
- 240000007228 Mangifera indica Species 0.000 abstract 2
- 235000014826 Mangifera indica Nutrition 0.000 abstract 2
- 101100243022 Mus musculus Pcnt gene Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003463 adsorbent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 abstract 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present utility model concerns anti-diabetes compositions comprising standardized pharmaceutical-grade Mangifera indica extract as active ingredient. Particularly, the present utility model concerns a composition of Mangifera indica tablet dosage form comprising Mangifera indica extract; diluent ingredient; disintegrant ingredient; flow activator; and adsorbent ingredient; wherein the Mangifera indica extract comprises at least 70 pcnt ethanolic extract of Mangifera indica.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PH22020050135U PH22020050135Y1 (en) | 2020-05-04 | 2020-05-04 | Anti-diabetes compositions comprising standardized mangifera indica extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PH22020050135U PH22020050135Y1 (en) | 2020-05-04 | 2020-05-04 | Anti-diabetes compositions comprising standardized mangifera indica extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH22020050135U1 PH22020050135U1 (en) | 2021-02-03 |
| PH22020050135Y1 true PH22020050135Y1 (en) | 2021-02-03 |
Family
ID=74551198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH22020050135U PH22020050135Y1 (en) | 2020-05-04 | 2020-05-04 | Anti-diabetes compositions comprising standardized mangifera indica extract |
Country Status (1)
| Country | Link |
|---|---|
| PH (1) | PH22020050135Y1 (en) |
-
2020
- 2020-05-04 PH PH22020050135U patent/PH22020050135Y1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH22020050135U1 (en) | 2021-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20062513L (en) | Compositions and dosage forms for enhanced absorption of metformin | |
| NO20071667L (en) | A pharmaceutical composition comprising levetiracetam and a process for the preparation of the composition | |
| MY148680A (en) | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base | |
| MY152185A (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | |
| CR9767A (en) | COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT Divisional application 7658 | |
| DK1370271T3 (en) | Process for the preparation of a matrix-containing plant preparation | |
| GEP20125704B (en) | Plk kinase inhibitors | |
| MX2009013462A (en) | Tableted compositions containing atazanavir. | |
| DK2178513T3 (en) | Tablet formulations containing atazanavir | |
| MX2021011823A (en) | Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine. | |
| MX2009013504A (en) | Tableted compositions containing atazanavir. | |
| MY147373A (en) | Piperazine derivatives as antimalarial agents | |
| WO2011141791A3 (en) | Extended release formulations of desvenlafaxine base | |
| WO2005065639A3 (en) | Novel pharmaceutical compositions | |
| PH22020050135U1 (en) | Anti-diabetes compositions comprising standardized mangifera indica extract | |
| MY153109A (en) | A solid pharmaceutical formulation | |
| MX2025006269A (en) | Fungicidal compositions | |
| DK0744947T3 (en) | Modified release metronidazole preparations and methods for their preparation and use | |
| MX2024001889A (en) | Deuterated compounds. | |
| MX2009013499A (en) | Tableted compositions containing atazanavir. | |
| CN102204557A (en) | Thiophanatemethyl and polyoxin antibacterial composition | |
| DK1765342T3 (en) | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for the preparation thereof | |
| PH22020050133U1 (en) | Anti-inflammatory compositions comprising standardized curcuma longa extract | |
| BG109404A (en) | Deramciclane-fumarate tablets | |
| DE502004007298D1 (en) | ORAL FORM FOR APPLICATION FOR HEAVY ACID AND AMPHOTERE ACTIVE SUBSTANCES |